Cochrane
Library

Cochrane Database of Systematic Reviews

De-escalation techniques for psychosis-induced aggression or agitation (Review)

Du M, Wang X, Yin S, Shu W, Hao R, Zhao S, Rao H, Yeung WL, Jayaram MB, Xia J

Du M, Wang X, Yin S, Shu W, Hao R, Zhao S, Rao H, Yeung WL, Jayaram MB, Xia J.
De-escalation techniques for psychosis-induced aggression or agitation.
Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD009922.
DOI: [10.1002/14651858.CD009922.pub2](https://doi.org/10.1002/14651858.CD009922.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
OBJECTIVES	5
METHODS	5
RESULTS	10
Figure 1.	11
DISCUSSION	12
AUTHORS' CONCLUSIONS	12
ACKNOWLEDGEMENTS	13
REFERENCES	14
CHARACTERISTICS OF STUDIES	17
ADDITIONAL TABLES	17
APPENDICES	19
WHAT'S NEW	19
CONTRIBUTIONS OF AUTHORS	19
DECLARATIONS OF INTEREST	20
SOURCES OF SUPPORT	20
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	20
INDEX TERMS	20

[Intervention Review]

De-escalation techniques for psychosis-induced aggression or agitation

Maolin Du¹, Xuemei Wang¹, Shaohua Yin¹, Wei Shu¹, Ruiqi Hao¹, Sai Zhao², Harish Rao³, Wan-Ley Yeung⁴, Mahesh B Jayaram⁵, Jun Xia²

¹School of Public Health, Inner Mongolia Medical University, Hohhot, China. ²Systematic Review Solutions Ltd, The Ingenuity Centre, The University of Nottingham, Nottingham, UK. ³Psychiatry, Borough Road and Nunthorpe Medical Group, Middlesbrough, UK. ⁴Bridge House Community Health Team, Leeds, UK. ⁵Department of Psychiatry, Melbourne Neuropsychiatry Centre, Melbourne, Australia

Contact address: Xuemei Wang, School of Public Health, Inner Mongolia Medical University, Jinshan Development District, Hohhot, Inner Mongolia, 010110, China. wangxm_zsu@163.com.

Editorial group: Cochrane Schizophrenia Group.

Publication status and date: Edited (no change to conclusions), published in Issue 4, 2017.

Citation: Du M, Wang X, Yin S, Shu W, Hao R, Zhao S, Rao H, Yeung WL, Jayaram MB, Xia J. De-escalation techniques for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2017, Issue 4. Art. No.: CD009922. DOI: [10.1002/14651858.CD009922.pub2](https://doi.org/10.1002/14651858.CD009922.pub2).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Aggression is a disposition, a willingness to inflict harm, regardless of whether this is behaviourally or verbally expressed and regardless of whether physical harm is sustained.

De-escalation is a psychosocial intervention for managing people with disturbed or aggressive behaviour. Secondary management strategies such as rapid tranquillisation, physical intervention and seclusion should only be considered once de-escalation and other strategies have failed to calm the service user.

Objectives

To investigate the effects of de-escalation techniques in the short-term management of aggression or agitation thought or likely to be due to psychosis.

Search methods

We searched Cochrane Schizophrenia Group's Study-Based Register of Trials (latest search 7 April, 2016).

Selection criteria

Randomised controlled trials using de-escalation techniques for the short-term management of aggressive or agitated behaviour. We planned to include trials involving adults (at least 18 years) with a potential for aggressive behaviour due to psychosis, from those in a psychiatric setting to those possibly under the influence of alcohol or drugs and/or as part of an acute setting as well. We planned to include trials meeting our inclusion criteria that provided useful data.

Data collection and analysis

We used the standard methodological procedures expected by Cochrane. Two review authors inspected all abstracts of studies identified by the search process. As we were unable to include any studies, we could not perform data extraction and analysis.

Main results

Of the 345 citations that were identified using the search strategies, we found only one reference to be potentially suitable for further inspection. However, after viewing the full text, it was excluded as it was not a randomised controlled trial.

Authors' conclusions

Using de-escalation techniques for people with psychosis induced aggression or agitation appears to be accepted as good clinical practice but is not supported by evidence from randomised trials. It is unclear why it has remained such an under-researched area. Conducting trials in this area could be influenced by funding flow, ethical concerns - justified or not - anticipated pace of recruitment as well the difficulty in accurately quantifying the effects of de-escalation itself. With supportive funders and ethics committees, imaginative trialists, clinicians and service-user groups and wide collaboration this dearth of randomised research could be addressed.

PLAIN LANGUAGE SUMMARY

De-escalation techniques for psychosis-induced aggression or agitation

Review question:

Are de-escalation techniques effective for managing psychosis-induced aggression or agitation?

Background

Aggression is a willingness to inflict harm, regardless of whether this is behaviourally or verbally expressed and regardless of whether physical harm is sustained.

De-escalation is a psychosocial intervention for management of aggressive or agitated behaviour. It uses techniques that help someone with aggression or agitation to self-monitor their emotions and self-manage their behaviour to try and stop aggressive behaviour escalating.

Searches

We ran electronic searches (last searched April 2016) for trials that randomised people with psychosis who were displaying aggressive or agitated behaviour to receive de-escalation techniques, standard care or other intervention to manage aggression. Three-hundred and forty-five records were found and checked by the review authors.

Results

No trials met the review requirements. There is no trial-based evidence currently available assessing the effectiveness of de-escalation techniques for managing aggression or agitation.

Conclusions

It is unclear why there are no randomised trials. Several issues such as cost, ethical considerations, difficulty recruiting people into trials, as well the ability to accurately quantify the effects of de-escalation itself could all be contributing factors. Meanwhile, de-escalation techniques are currently used without any trial-based evidence that they are effective.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. De-escalation for aggression thought to be due to psychosis versus standard care

Patient or population: people who are aggressive secondary to serious mental illness

Settings: anywhere

Intervention: de-escalation versus standard care

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Partici- pants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Standard care control	De-escalation technique				
Clinically important changes in global state	We identified no relevant studies.					
Aggression - Improved to an important extent						
Aggression - deterioration: incidence of violence to self or others						
Aggression - changes in aggression as recorded by any other outcomes						
Adverse effects - physical adverse effects						
Adverse effects - death, suicide or natural causes						
Adverse effects - psychological adverse effects						

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

BACKGROUND

Description of the condition

Aggression is a range of behaviours or actions to inflict harm, hurt or injury to another person regardless of whether this is behaviourally or verbally expressed and regardless of whether physical harm is sustained or intention is clear (NICE 2015). Aggression can present in a variety of settings including emergency rooms, inpatient unit, community and primary care settings and some times in police cells. Untreated, this can quickly escalate risks to the patient, healthcare professionals and family members who are often victims of violence (Bourget 2002; Maguire 2007).

The incidence of aggression is more frequent in emergency departments (25%) and inpatient psychiatric hospitals (32.4%) (Bowers 2011; NHS Protect 2013). The relationship between psychosis and violence is uncertain. There is some evidence to suggest that individuals with a mental disorder/severe mental disorder are more likely to be violent than the general population (Fazel 2006; van Dorn 2012); however others have argued that it is substance misuse, instead of a mental health problem itself that increases the risk for violence (Elbogen 2009). A recently published guideline indicated that a mental disorder is probably only a predictive factor of violence, and that substance misuse is more likely related to the incidence of violence (NICE 2015). Swift containment of the situation is essential and preventive de-escalation techniques, such as restraint, should be utilised prior to interventional measures for the management of aggression (NICE 2015).

Description of the intervention

De-escalation is an intervention using emotional regulation or self-management techniques to avert aggressive or violent behaviour (NICE 2015). 'The assault cycle' typically includes a trigger phase, escalation phase, crisis phase, recovery phase and depression phase (Kaplan 1983). De-escalation is a complex range of skills designed to abort the assault cycle during the escalation phase, and this includes both verbal and non-verbal communication skills (CRAG 1996).

De-escalation is part of the process of managing aggression and is usually recommended as either a preventative measure or an early step to prevent deterioration in the patient's condition. Secondary management strategies such as rapid tranquillisation, physical intervention and seclusion should only be considered once de-escalation and other strategies have failed to calm the service user (NICE 2015). Regrettably, these recommendations are impractical in most emergency medical settings in developing countries, where resources are strained by heavy patient loads and understaffing, and where a sleeping patient is better than one who needs constant observation to assess the need for tranquillisation. From the patient's perspective, being asleep is also less traumatic than being physically restrained (Andrade 2007).

How the intervention might work

There are competing theoretical approaches to de-escalation, including verbal de-escalation. Some approaches make use of communication theory (Paterson 1997), others of situational analysis (Rix 2001). All approaches emphasise the need to observe for signs and symptoms of anger and agitation, approaching the person in a calm controlled manner, giving choices and maintaining

the service user's dignity. Some approaches suggest mirroring the patient's mood.

De-escalation methods help by establishing a positive therapeutic alliance with the patient, and the active collaboration of the patient in the treatment process with behavioural expectations and prescribed treatments it makes it easier to manage patient-staff conflicts and de-escalate aggressive episodes (Levenson 2004).

Why it is important to do this review

Guidelines recommend de-escalation as an intervention in their algorithms for managing patients with acute aggression (NICE 2015). A recent report notes that, despite the emphasis that is often placed on the importance of de-escalation, little research has been carried out into the effectiveness of any given approach, leaving nurses to contend with conflicting advice and theories. Also, a survey of guidelines suggests that recommendations based on NICE were of (grade D) and there were no trials or systematic reviews in this area. There is also lack of evidence regarding effectiveness of rapid tranquillisation, physical intervention and seclusion (Yeung 2009).

There is no standard approach to de-escalation (Paterson 1997). There has been little research conducted into the effectiveness of different approaches to de-escalation, or, for that matter, into the effectiveness of training in any given approach. There is thus an urgent need to systematically review the available evidence evaluating the effectiveness of de-escalation in managing patients with acute aggression.

This is one of a series of related Cochrane reviews (Table 1).

OBJECTIVES

To investigate the effects of de-escalation techniques in the short-term management of aggression or agitation thought or likely to be due to psychosis.

METHODS

Criteria for considering studies for this review

Types of studies

We planned to select all relevant randomised controlled trials using de-escalation techniques for the management of aggressive behaviour. If a trial was described as 'double blind' but implied randomisation, we would have included such trials in a sensitivity analysis (see Sensitivity analysis). We planned to exclude quasi-randomised studies, such as those allocating by alternate days of the week. For trials where people were given additional treatments, we would have included the data if the adjunct treatment was evenly distributed between groups and it was only the de-escalation that was randomised.

Types of participants

We would have included adults (at least 18 years) with a potential for aggressive behaviour due to psychosis, from those in a psychiatric setting to those possibly under the influence of alcohol or drugs and/or as part of an acute setting as well.

Types of aggressive behaviours can include the following.

1. Verbal abuse

2. Non-verbal abuse
3. Physical violence to self/others
4. Threatening behaviours
5. Assault

Types of interventions

1. De-escalation:

NICE 2015 defines de-escalation as the use of techniques (including verbal and non-verbal communication skills) aimed at defusing anger and averting aggression. Prescribed 'as required' ('*pro re nata*' or p.r.n.) medication can be used as part of a de-escalation strategy but, used alone is not de-escalation.

There are various techniques that can be used to defuse an aggressive situation.

1. Verbal communication techniques
2. Use of body language
3. Prevention and recognition strategies (risk assessment tools)
4. Staff attitudes, knowledge and skills
5. Setting of limits for patients to follow
6. Environmental controls (such as minimising light, noise, conversations and so on) used for the management of aggression

De-escalation does not involve restraint, medication used alone or seclusion.

We planned to include trials that used the above techniques specifically during, or prior to, aggressive or agitated behaviour.

Types of outcome measures

The effects of de-escalation techniques for managing aggression would usually be immediate (15 minutes) to short term (one to two hours).

Primary outcomes

1. Clinically important change in global state: as defined by studies

2. Aggression

- 2.1 Improved to an important extent
- 2.2 Deterioration: incidence of violence to self or others (harm)
- 2.3 Changes in aggression as recorded by any other outcomes

3. Adverse effects

- 3.1 Physical adverse effects
- 3.2 Death, suicide or natural causes
- 3.3 Psychological adverse effects

Secondary outcomes

1. Global state

- 1.1 Relapse: as defined by individual studies
- 1.2 Any change in global state

2. Mental state

- 2.1 Changes to mental state deemed clinically significant by study
- 2.2 Continuous measures of mental state
- 2.3 Psychiatric symptoms

3. Leaving the study early

4. Service use

- 4.1 Hospital admission
- 4.2 Length of stay in hospital
- 4.3 Changes to hospital status

5. Social functioning

- 5.1 Continuous measures in social functioning

6 Satisfaction

- 6.1 Patient satisfaction
- 6.2 Carer satisfaction
- 6.3 Changes to quality of life defined as significant by individual studies

7. Economic outcomes

8. Aggression/behaviour

- 8.1 Changes in verbal aggression
- 8.2 Changes in violence towards objects
- 8.3 Other changes in behaviour

'Summary of findings' table

We intended to use the GRADE approach to interpret findings (Schünemann 2008) and to use the GRADE profiler (GRADEPRO) to import data from RevMan 5 (Review Manager) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient-care and decision making. We intended to select the following main outcomes for inclusion in the 'Summary of findings' table.

1. Clinically important changes in global state (short-term outcomes)

2. Aggression

- 2.1 Improved to an important extent
- 2.2 Deterioration: incidence of violence to self or others (harm)
- 2.3 Changes in aggression as recorded by any other outcomes

3. Adverse effects

- 3.1 Physical adverse effects
- 3.2 Death, suicide or natural causes
- 3.3 Psychological adverse effects

Search methods for identification of studies

No language or publication status restriction was applied within the limitations of the search tools.

Electronic searches

Cochrane Schizophrenia Group's Study-based Register of Trials

On 7 April, 2016, the Information Specialist searched the register using the following search strategy which has been developed based on literature review and consulting with the authors of the review:

((Aggress* OR *Agitat* OR *Violen*) in Title OR Abstract of REFERENCE OR Intervention of STUDY) AND ((*De-Escalat* OR *Deescalat* OR *De-Stimulat* OR *Destimulat* OR *De-Fus*

OR *Defus* OR *One-To-One* OR *One To One* OR *Diffuse* OR *Calming* OR *Non Aversive* OR *Non-Aversive* OR *Non Confrontat* OR *Non-Confrontat* OR *Psycho Social* OR *Psycho-Social* OR *Verbal* OR *Talk* OR *Nurse* Role*) in Title OR Abstract of REFERENCES)

In such a study-based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.

This register is compiled by systematic searches of major resources (including MEDLINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries of clinical trials), and their monthly updates, handsearches, grey literature, and conference proceedings (see [Group's Module](#)). There is no language, date, document type, or publication status limitations for inclusion of records into the register.

For previous searches, please see [Appendix 1](#).

Searching other resources

1. Reference searching

We would have inspected the references of all included studies for further relevant studies.

2. Personal contact

We would have contacted the first author of each included study for information regarding unpublished trials.

Data collection and analysis

Selection of studies

Review authors WY and HR inspected all abstracts of studies identified as above for potentially relevant reports. In addition, to ensure reliability, review author MBJ inspected a random sample of these abstracts, comprising 20% of the total. Where disagreement occurred, this was resolved by discussion, or where there was still doubt, we obtained the full article for further inspection. We acquired the full article of the relevant report for reassessment and carefully inspected for a final decision on inclusion (see [Criteria for considering studies for this review](#)). Once the full article was obtained, in turn MD and WS inspected the full report and independently decided whether it met inclusion criteria. MD and WS were not blinded to the names of the authors, institutions or journal of publication.

Data extraction and management

1. Extraction

Review author MD and SY would have extracted data from all included studies. In addition, to ensure reliability, if trials had been found, XW would have independently extracted data from a random sample of these studies, comprising 20% of the total. Again, we would have discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. With remaining problems, XW would have helped clarify issues and we would have documented these final decisions. We would have extracted data presented only in graphs and figures whenever possible, but included the data only if two review authors independently had the same result. We would have

attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi-centre, where possible, we would have extracted data relevant to each component centre separately.

2. Management

2.1 Forms

We planned to extract data onto standard, simple forms.

2.2 Scale-derived data

We would have included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had been described in a peer-reviewed journal ([Marshall 2000](#)); and
b. the measuring instrument had not been written or modified by one of the trialists for that particular trial.

Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, and we would have noted in the 'Description of studies' if this was the case or not.

c) the instrument should be a global assessment of an area of functioning and not sub-scores which are not, in themselves, validated or shown to be reliable. However there are exceptions, and we would have included sub-scores from mental state scales measuring positive and negative symptoms of schizophrenia.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We would have combined endpoint and change data in the analysis as we would have preferred to use mean differences (MD) rather than standardised mean differences (SMD) throughout ([Higgins 2011](#)).

2.4 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we planned to apply the following standards to all data before inclusion:

- standard deviations (SDs) and means are reported in the paper or obtainable from the authors;
- when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, ([Altman 1996](#));
- if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, [Kay 1986](#)), which can have values from 30 to 210), we planned to modify the calculation described above to take the scale starting point into account. In these cases skew is present if $2\text{ SD} > (S - S_{\min})$, where S is the mean score and $S_{\min}$ is the minimum score.

Endpoint scores on scales often have a finite start and end point and these rules can be applied. We would have presented skewed endpoint data from studies of less than 200 participants as other

data within the data analyses section rather than in analyses. Skewed data pose less of a problem when looking at means if the sample size is large (> 200) and we would have entered these into the syntheses.

When continuous data are presented on a scale that include a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We would have entered change data, regardless of sample size, into the analyses.

2.5 Common measure

To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

2.6 Conversion of continuous to binary

Where possible, we would have made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the PANSS (Kay 1986), this could be considered as a clinically significant response (Leucht 2005; Leucht 2005a). If data based on these thresholds were not available, we would have used the primary cut-off presented by the original authors.

2.7 Direction of graphs

Where possible, we would have entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for de-escalation. Where keeping to this would have made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not improved'), we would have reported data where the left of the line indicates an unfavourable outcome. This would have been noted in the relevant graphs.

Assessment of risk of bias in included studies

Again, review authors MD and WS would have worked independently to assess risk of bias using criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.

If the raters disagreed, the final rating would have been made by consensus, with the involvement of another member (SZ) of the review group. If inadequate details of randomisation and other characteristics of trials had been provided, we would have contacted the authors of the studies in order to obtain further information. We would have reported non-concurrence in quality assessment, but if disputes had arisen as to which category a trial was to be allocated, again, resolution would have been made by discussion.

We would have noted the level of risk of bias in both the text of the review and in the 'Summary of findings' table.

Measures of treatment effect

1. Binary data

For binary outcomes, we would have calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).

2. Continuous data

For continuous outcomes, we would have estimated the MD between groups. We prefer not to calculate effect size measures (SMD). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

Unit of analysis issues

1. Cluster trials

Studies increasingly employ 'cluster-randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

Where clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We would have sought to contact first authors of such studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and adjusted for this by using accepted methods (Gulliford 1999). Where clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.

We were advised that we needed to reduce the size of each trial to its 'effective sample size' (Rao 1992). The effective sample size of a single intervention group in a cluster-randomised trial is its original sample size divided by a quantity called the 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was not reported, we would have assumed it to be 0.1 (Ukomunne 1999). A common design effect is usually assumed across intervention groups. For dichotomous data, both the number of participants and the number experiencing the event are divided by the same design effect. Since the resulting data must be rounded to whole numbers for entry into RevMan, this approach may be unsuitable for small trials. For continuous data, only the sample size needs to be reduced; means and SDs should remain unchanged.

2. Cross-over trials

A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, the participants can differ systematically from their initial state despite a wash-out

phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, we would have only used data from the first phase of cross-over studies.

3. Studies with multiple treatment groups

Where a study involved more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. If data were binary, we simply would have added and combined them within the two-by-two table. If data were continuous, we would have combined data following the formula in section 7.7.3.8 (Combining groups) of the *Cochrane Handbook for Systematic Reviews of Interventions*. Where the additional treatment arms were not relevant, we would not present these data.

Dealing with missing data

1. Overall loss of credibility

At some degree of loss of follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not present these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have marked such data with (*) to indicate that such a result may well be prone to bias.

2. Binary

In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we would have presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early would all be assumed to have the same rates of negative outcome as those who completed, with the exception of the outcomes of death and adverse effects. For these outcomes, the rate of those who stayed in the study - in that particular arm of the trial - would be used for those who did not. We would have undertaken a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared with the intention-to-treat analysis using the above assumptions.

3. Continuous

3.1 Attrition

In the case where attrition for a continuous outcome was between 0% and 50% and data only from people who completed the study to that point were reported, we would have reproduced these.

3.2 Standard deviations (SDs)

If SDs were not reported, we would have first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either 'P' value or 't' value available for differences in mean, we would have calculated them according to the rules described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). When only the SE is reported, SDs can be calculated by the formula $SD = SE \times \text{square root } (n)$. Chapters 7.7.3 and 16.1.3 (Higgins 2011) present detailed formulae for estimating SDs from P values, t or F values, confidence

intervals, ranges or other statistics. If these formulae did not apply, we would have calculated the SDs according to a validated imputation method, based on the SDs of other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless would have examined the validity of the imputations in a sensitivity analysis excluding imputed values.

3.3 Last observation carried forward

We anticipated that in some studies the method of last observation carried forward (LOCF) would have been employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (Leucht 2007). Therefore, where LOCF data had been used in the trial, if less than 50% of the data had been assumed, we would have reproduced these data and indicated that they were the product of LOCF assumptions.

Assessment of heterogeneity

1. Clinical heterogeneity

We planned to consider all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We would have simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. If such situations or participant groups had been noted, these would have been fully discussed.

2. Methodological heterogeneity

We would have considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We would have simply inspected all studies for clearly outlying methods which we had not predicted would arise. If such methodological outliers had been noted, these would have been fully discussed.

3. Statistical heterogeneity

3.1 Visual inspection

We would have visually inspected graphs to investigate the possibility of statistical heterogeneity.

3.2 Employing the I^2 statistic

We intended to investigate heterogeneity between studies by considering the I^2 method alongside the Chi^2 'P' value. The I^2 provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I^2 depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi^2 test, or a confidence interval for I^2). An I^2 estimate greater than or equal to around 50% accompanied by a statistically significant Chi^2 statistic, is interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 - Higgins 2011). If substantial levels of heterogeneity had been found in the primary outcome, we would have explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).

Assessment of reporting biases

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997).

These are described in Section 10 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We would not have used funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we would have sought statistical advice in their interpretation.

Data synthesis

We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

We anticipated one subgroup analysis to test the hypothesis that de-escalation is most effective for those with acute aggression. We hoped to present data for this subgroup for the primary outcomes.

2. Investigation of heterogeneity

If inconsistency was high, we would have reported this. First, we would have investigated whether data had been entered correctly. Second, if data had been entered correctly, we would have visually inspected the graph and successively removed outlying studies to see if homogeneity was restored. For this review, we had decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present the data. If not, we would not pool data but discuss the issues. We know of no supporting research for this 10% cut-off but considered investigating the use of prediction intervals as an alternative to this unsatisfactory state. If unanticipated clinical or methodological heterogeneity were obvious, we would have simply stated hypotheses regarding these for future reviews or versions of this review. We would not have anticipated undertaking analyses relating to these.

Sensitivity analysis

1. Implication of randomisation

We aimed to include trials in a sensitivity analysis if they were described in some way to imply randomisation. For the primary outcomes, we aimed to include these studies and if their inclusion did not result in a substantive difference, they would have remained in the analyses. If their inclusion resulted in important clinically significant, but not necessarily statistically significant differences, we would not have added the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory.

2. Assumptions for lost binary data

Where assumptions had to be made regarding people lost to follow-up (see [Dealing with missing data](#)), we planned to compare the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. If there was a substantial difference, we planned to report results and to discuss them, but would have continued to employ our assumption.

Where assumptions had to be made regarding missing SDs data (see [Dealing with missing data](#)), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis would have been undertaken to test how prone results were to change when completer-only data only were compared with the imputed data using the above assumption. If there was a substantial difference, we would report results and discuss them but would continue to employ our assumption.

RESULTS

Description of studies

Results of the search

Over 300 records were identified using the search criteria. No record met the inclusion criteria (please refer to [Figure 1](#) for study screening flow diagram).

Figure 1. Study flow diagram.

Included studies

We were unable to include any study in this review.

Excluded studies

We assessed [Nijman 1997](#), but we excluded this trial as it was not randomised. We identified no registered clinical ongoing studies. No studies are awaiting assessment.

Risk of bias in included studies

Allocation

There were no included studies to assess risk of bias.

Blinding

There were no included studies to assess risk of bias.

Incomplete outcome data

There were no included studies to assess risk of bias.

Selective reporting

There were no included studies to assess risk of bias.

Other potential sources of bias

There were no included studies to assess risk of bias.

Effects of interventions

See: [Summary of findings for the main comparison De-escalation for aggression thought to be due to psychosis versus standard care](#)

There were no randomised controlled trials identified comparing the effect of interventions with de-escalation techniques in managing psychosis-induced aggression.

DISCUSSION

Summary of main results

Of the 345 studies identified from the search, none were found suitable to include in the review. In summary, no trial-based evidence is available for any of the key outcomes of clinical relevance ([Summary of findings for the main comparison](#)).

Overall completeness and applicability of evidence

There were no randomised controlled trials relevant to the review and hence, we are unable to make any inferences about applicability. Because of the broad scope of what could be considered 'de-escalation', it is possible that very wide-ranging and less precise searching may find occasional trials of some relevance to this area. However, we think it unlikely that we have missed large relevant studies.

Quality of the evidence

There were no randomised controlled trials identified relevant to this review

Potential biases in the review process

We searched for published and unpublished trials and two review authors screened the potential studies. It is possible that our English language searching failed to identify trials, but important

studies such as would be expected for this review are probably likely to be published in journals indexed by the major databases we had searched.

Agreements and disagreements with other studies or reviews

[Hockenhuill 2012](#) revealed extensive literature that does exist in this field. Unfortunately the studies included in this review were low quality. Much of the research is opportunistic by practitioners on the basis of what is possible within their own clinical setting. Although this is laudable as a contribution to the principle of evidence-based practice, without adequate resources to improve study design, the cumulative evidence base may never allow conclusions to be made that are strong enough to direct policy. We know of no robust quantification of the effects of de-escalation techniques.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with schizophrenia

The incidents where de-escalation could be employed is often a traumatic time for the service user and staff involved and some de-escalation techniques are recommended as part of various policy documents ([NICE 2015](#)). Unfortunately, this recommendation appears to be based on what is acceptable as good clinical practice rather than being supported by more objective evidence. Recognising that deploying a de-escalation technique would tend to occur when a person with serious mental illness was felt to be out of control, people with schizophrenia or other psychotic illnesses may feel powerless to change the dearth of evidence. This is not so. Advanced directives could advise clinicians to take heed and use only de-escalation elements that are acceptable to the patient, and service-user groups could lobby for, and help create, useful trials in this area.

2. For clinicians

In the mental health setting, dealing with aggressive patients can be an everyday occurrence for healthcare professionals. Patient death or injury resulting from the use of restraint and seclusion is an increasing concern. In a report from the USA, there were 142 restraint-related deaths over a decade, 40% of which were attributed to unintentional asphyxiation during restraint ([Weiss 1998](#)). Restraint not only poses a risk of harm for the patient, but is also physically and emotionally traumatising for staff involved in the process. It has also been pointed out that "high restraint rates are now understood as evidence of treatment failure" ([Stefan 2002](#)).

In Leeds and York Partnerships NHS Foundation Trust, between January 2012 and December 2012, data from the Trust's critical incident reports showed that there were a total of 5153 incidents, of which nearly 20% (908) involved restraint. Of these, 67% (680) incidents involved more than two members of staff. Five-hundred and sixty three (83.5%) of these incidents involved at least four staff members in each incident. Nearly 2200 person-hours have been used up in managing aggression at mental health units in Leeds ([LYPFT 2013](#)). A survey of staff knowledge of de-escalation practices in Leeds and York Partnerships NHS Trust ([Rao 2013](#)) showed that most staff agreed that it was a positive thing to have training in de-escalation along with breakaway techniques and restraint. Nearly

half of the staff were able to identify the varied situations where aggression could be de-escalated. Only 50% of the staff stated, however, that they would ensure their own safety when faced with an aggressive patient with whom they had to deal.

3. For policymakers

Current research in this area has not produced evidence of any effects. Should training in such techniques be encouraged, this encouragement should be based on more than well-meaning sentiment. Objective meaningful outcomes are possible to investigate from well-designed, conducted and reported randomised trials (please see [Implications for research](#)).

Implications for research

1. Reviews

Perhaps with broadening of the search, trials could be found but it seems unlikely that we have missed any large studies. It would seem important to regularly maintain this review as wide dissemination of the first trials in this area should aid clinical impact. As use of 'as required' medication can be part of de-escalation ([Douglas-Hall 2015](#)), it would also seem important that this review is regularly maintained.

2. Trials

Other researchers have investigated de-escalation in acute aggression for people with Alzheimer's disease with randomised

trials for "Snoezelen" ([Andreeva 2011](#)), relaxing and music therapy ([Casby 1994](#)), simulated family presence ([Garland 2007](#)), therapeutic and simulated therapeutic touch ([Hawranik 2008](#)) and lavender aromatherapy ([Lee 2005](#)). It is not impossible to undertake trials in this very difficult area. Previous study designs for adults with general psychotic problems and aggression have included single-group pre- and post-, quasi-experimental techniques. There is clearly a need to conduct randomised control trials in this area. We do realise that such a design takes much careful consideration and negotiation, but we have given this area some thought and suggest an outline for a design of future trials ([Table 2](#)).

ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

The search terms for the protocol were developed, in collaboration with the review authors, by the Information Specialist of the Cochrane Schizophrenia Group, Samantha Roberts. We would like to thank Mohamed Gomaa and Seyed Mazloomi for peer reviewing this version of the review.

REFERENCES

References to studies excluded from this review

Nijman 1997 {published data only}

Nijman HL, Merckelbach HL, Allertz WF, a Campo JM. Prevention of aggressive incidents on a closed psychiatric ward. *Psychiatric Services* 1997;**48**(5):694-8. [MEDLINE: 9144826]

Additional references

Ahmed 2010

Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2010, Issue 4. [DOI: [10.1002/14651858.CD007445.pub2](https://doi.org/10.1002/14651858.CD007445.pub2); PUBMED: 20393959]

Ahmed 2011

Ahmed U, Rehman F, Jones H, Adams CE. Risperidone for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2011, Issue 11. [DOI: [10.1002/14651858.CD009412](https://doi.org/10.1002/14651858.CD009412)]

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200.

Andrade 2007

Andrade C. Rapid Tranquillisation in emergency psychiatric settings. *BMJ* 2007;**335**:835.

Andreeva 2011

Andreeva V, Dartinet-Chalmey V, Kloul A, Fromage B, Kadri N. "Snoezelen": Multisensorial stimulation effects on behavioural problems in elderly demented patients ["Snoezelen" ou les effets de la stimulation multisensorielle sur les troubles du comportement chez les personnes âgées démentes à un stade avancé]. *NPG Neurologie - Psychiatrie - Geriatrie* 2011;**11**(61):24-9.

Belgamwar 2005

Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. *Cochrane Database of Systematic Reviews* 2005, Issue 2. [DOI: [10.1002/14651858.CD003729.pub2](https://doi.org/10.1002/14651858.CD003729.pub2)]

Berk 2004

Berk M, Rathbone J, Mandriota-Carpenter SL. Clotiapine for acute psychotic illnesses. *Cochrane Database of Systematic Reviews* 2004, Issue 4. [DOI: [10.1002/14651858.CD002304.pub2](https://doi.org/10.1002/14651858.CD002304.pub2)]

Bland 1997

Bland JM. Trials randomised in clusters. *BMJ* 1997;**315**:600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3 Comparison of the indices and their use [Aperçu sur la problematiquedes indices d'efficacite therapeutique 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. *Therapie* 1999;**54**(4):405-11.

Bourget 2002

Bourget D, El-Guebaly N, Atkinson M. Assessing and managing violent patients. *CPA Bulletin de l'APC* 2002:25-7.

Bowers 2011

Bowers L, Stewart D, Papadopoulos C, Dack C, Ross J, Khanom D. Inpatient violence and aggression: A literature review. Report from the Conflict and Containment Reduction Research Programme. <http://www.kcl.ac.uk/ioppn/depts/hspr/research/ciemh/mhn/projects/litreview/LitRevAgg.pdf> 2011 [Accessed 06/02/2017].

Casby 1994

Casby JA, Holm MB. The effect of music on repetitive disruptive vocalizations of persons with dementia. *American Journal of Occupational therapy* 1994;**48**(10):883-9.

CRAG 1996

Clinical Research and Audit Guidelines (CRAG) Working Group on Mental Illness. The prevention and management of aggression - a good practice statement. Scottish Office, National Health Service in Scotland 1996. [ISBN 0748031448, 9780748031443]

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behaviour. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. *Statistics in Medicine* 2002;**21**:2971-80.

Douglas-Hall 2015

Douglas-Hall P, Whicher EV. 'As required' medication regimens for seriously mentally ill people in hospital. *Cochrane Database of Systematic Reviews* 2015, Issue 12. [DOI: [10.1002/14651858.CD003441.pub3](https://doi.org/10.1002/14651858.CD003441.pub3); CD003441]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629-34.

Elbogen 2009

Elbogen EB, Johnson SC. The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry* 2009;**66**:152-61.

Elbourne 2002

Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-

over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

Fazel 2006

Fazel S, Grann M. The population impact of severe mental illness on violent crime. *American Journal of Psychiatry* 2006;**163**:1397-403.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(7):7-10.

Garland 2007

Garland K, Beer E, Eppingstall B, O'Connor DW. A comparison of two treatments of agitated behaviour in nursing home residents with dementia: Simulated family presence and preferred music. *American Journal of Geriatric Psychiatry* 2007;**15**(6):514-21.

Gillies 2013

Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2013, Issue 4. [DOI: [10.1002/14651858.CD003079.pub3](https://doi.org/10.1002/14651858.CD003079.pub3)]

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Psychiatry* 1978;**135**(3):325-8.

Hawranik 2008

Hawranik P, Johnson P, Deatrich J. Therapeutic touch and agitation in individuals with Alzheimer's disease. *Western Journal of Nursing Research* 2008;**30**:417-34.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hockenhull 2012

Hockenhull JC, Whittington R, Leitner M, Barr W, McGuire J, Cherry MG, et al. A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8. *Health Technology Assessment* 2012;**16**(3):1-152.

Huf 2016

Huf G, Alexander J, Gandhi P, Allen M. Haloperidol plus promethazine for psychosis-induced aggression. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, 2016, issue 11. [DOI: [10.1002/14651858.CD005146.pub3](https://doi.org/10.1002/14651858.CD005146.pub3); CD005146]

Jayakody 2012

Jayakody K, Gibson RC, Kumar A, Gunadasa S. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. *Cochrane Database of Systematic Reviews* 2012, Issue 4. [DOI: [10.1002/14651858.CD000525.pub3](https://doi.org/10.1002/14651858.CD000525.pub3)]

Kaplan 1983

Kaplan S, Wheeler E. Survival skills for working with potentially violent clients. *Social Casework* 1983;**64**(6):339-46.

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.

Khokhar 2016

Khokhar MA, Rathbone J. Droperidol for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2016, Issue 12. [DOI: [10.1002/14651858.CD002830.pub3](https://doi.org/10.1002/14651858.CD002830.pub3)]

Khushu 2016

Khushu A, Powney MJ. Haloperidol for long-term aggression in psychosis. *Cochrane Database of Systematic Reviews* 2016, Issue 11. [DOI: [10.1002/14651858.CD009830.pub2](https://doi.org/10.1002/14651858.CD009830.pub2)]

Lee 2005

Lee SY. The effect of lavender aromatherapy on cognitive function, emotion, and aggressive behaviour of elderly with dementia. *Taehan Kanho Hakhoe Chi* 2005;**35**(2):303-12.

Leucht 2005

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231-8. [PUBMED: 15982856]

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. *British Journal of Psychiatry* 2005;**187**:366-71.

Leucht 2007

Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artefact of LOCF?. *Schizophrenia Bulletin* 2007;**33**(1):183-91.

Levenson 2004

Levenson JL. *American Psychiatric Publishing Book of Psychosomatic Medicine*. American Psychiatric Association, 2004.

LYPFT 2013

Leeds and York Partnerships NHS Trust. Innovation Research and Development Newsletter 2013; Vol. March, issue 13:1-19.

Maguire 2007

Maguire J, Ryan D. Aggression and violence in mental health services: categorizing the experiences of Irish nurses. *Journal of Psychiatric and Mental Health Nursing* 2007;**14**:120-7.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

Muralidharan 2006

Muralidharan S, Fenton M. Containment strategies for people with serious mental illness. *Cochrane Database of Systematic Reviews* 2006, Issue 3. [DOI: [10.1002/14651858.CD002084.pub2](https://doi.org/10.1002/14651858.CD002084.pub2)]

NHS Protect 2013

NHS Protect. Reported physical assaults on NHS staff figures (2012-2013). Available from: <http://www.nhscounterfraud.nhs.uk/2012-13%20Reported%20physical%20assaults%20on%20NHS%20staff%20NO%20PCT%20&%20SHA%20v2%20PCC.pdf>. London: NHS Security Management Services 2013.

NICE 2015

Violence and aggression: short-term management in mental health, health and community settings. NICE guidelines [NG10] May 2015.

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale. *Psychological Reports* 1962;**10**:799-812.

Paterson 1997

Paterson B, Leadbetter D, McComish A. De escalation in the short term management of violence - A process based approach. *Nursing Times* 1997;**93**(36):58-61.

Powney 2012

Powney MJ, Adams CE, Jones H. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: [10.1002/14651858.CD009377.pub2](https://doi.org/10.1002/14651858.CD009377.pub2); PUBMED: 23152276]

Rao 1992

Rao JNK, Scott AJ. A simple method for the analysis of clustered binary data.. *Biometrics* 1992;**48**:577-85.

Rao 2013

Rao H. Survey of management techniques among staff in acute inpatient mental health units in LYPFT. MSc Psychiatry Dissertation 2013.

Rix 2001

Rix R. De-escalation techniques. In: Beer MD, Pereira SM, Paton C editor(s). *Psychiatric Intensive Care*. GreenwichMedical Media Limited, 2001.

Sailas 2000

Sailas E, Fenton M. Seclusion and restraint for people with serious mental illnesses. *Cochrane Database of Systematic Reviews* 2000, Issue 2. [DOI: [10.1002/14651858.CD001163](https://doi.org/10.1002/14651858.CD001163)]

Schünemann 2008

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing

conclusions. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration, 2008:359-83.

Spencer 2016

Spencer S, Johnson P. De-escalation techniques for managing aggression. *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, 2016, issue 1. [DOI: [10.1002/14651858.CD012034](https://doi.org/10.1002/14651858.CD012034); CD012034]

Stefan 2002

Stefan S. Legal and regulatory aspects of seclusion and restraint in mental health settings. Special edition: Violence and Coercion in Mental Health Settings: Eliminating the Use of Seclusion and Restraint. NTAC Networks. 2002;Summer/Fall; Vol. 3.

Toal 2012

Toal F, Roberts K. Clozapine for people with schizophrenia and recurrent physical aggression. *Cochrane Database of Systematic Reviews*.

Ukomunne 1999

Ukomunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review [Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review]. *Health Technology Assessment* 1999;**3**:5.

van Dorn 2012

van Dorn R, Volavka J, Johnson N. Mental disorder and violence: is there a relationship beyond substance use?. *Social Psychiatry and Psychiatric Epidemiology* 2012;**47**:487-503.

Vangala 2012

Vangala R, Ahmed U, Ahmed R. Loxapine inhaler for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: [10.1002/14651858.CD010190](https://doi.org/10.1002/14651858.CD010190)]

Weiss 1998

Weiss EM. Deadly restraint: a Hartford Courant investigative report. *Hartford Courant*. October 1998;**Section A.1**:11-5.

Wilkie 2012

Wilkie F, Fenton M. Quetiapine for psychosis-induced aggression or agitation. *Cochrane Database of Systematic Reviews* 2012, Issue 4. [DOI: [10.1002/14651858.CD009801](https://doi.org/10.1002/14651858.CD009801)]

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. *Psychiatric Bulletin* 2009;**33**(7):254-7.

Yeung 2009

Yeung W-L, Jayaram M, Kotha S, Adams CE. Is NICE nice? RCGP Annual National Primary Care Conference, Excellence in Practice: winning ways for primary care; 2009 Nov 5-7; Glasgow. 2009.

References to other published versions of this review

Database of Systematic Reviews 2012, Issue 7. [DOI: [10.1002/14651858.CD009922](https://doi.org/10.1002/14651858.CD009922)]

Rao 2012

Rao H, Yeung WL, Jayaram MB. De-escalation techniques for psychosis-induced aggression or agitation. *Cochrane*

CHARACTERISTICS OF STUDIES

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Nijman 1997	Allocation: not randomised.

ADDITIONAL TABLES

Table 1. Other relevant Cochrane reviews

Focus of review	Reference
Completed and maintained reviews	
'As required' medication regimens for seriously mentally ill people in hospital	Douglas-Hall 2015
Benzodiazepines for psychosis-induced aggression or agitation	Gillies 2013
Chlorpromazine for psychosis-induced aggression or agitation	Ahmed 2010
Clotiapine for acute psychotic illnesses	Berk 2004
Containment strategies for people with serious mental illness	Muralidharan 2006
Droperidol for acute psychosis	Khokhar 2016
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)	Powney 2012
Haloperidol plus promethazine for psychosis-induced aggression	Huf 2016
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses	Belgamwar 2005
Seclusion and restraint for serious mental illnesses	Sailas 2000
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses	Jayakody 2012
Reviews in the process of being completed	
Clozapine for people with schizophrenia and recurrent physical aggression	Toal 2012
De-escalation techniques for managing aggression	Spencer 2016
Haloperidol for long-term aggression in psychosis	Khushu 2016

Table 1. Other relevant Cochrane reviews *(Continued)*

Loxapine inhaler for psychosis-induced aggression	Vangala 2012
Quetiapine for psychosis-induced aggression or agitation	Wilkie 2012
Risperidone for psychosis-induced aggression or agitation	Ahmed 2011

Table 2. Outline design for a randomised trial of de-escalation technique

Methods	Allocation: cluster-randomised, clearly described, with researched and recorded intra-class correlation coefficient (ICC) reported. Blinding: none. Duration: 2 weeks. Setting: any psychiatric ward with high rate of aggression.
Participants	Diagnosis: any. History: people admitted or, or getting admitted to psychiatric ward. N =*. Age: adult. Sex: men or women. Exclude: those already randomised.
Interventions	1. De-escalation technique training. 2. Waiting list for training. The de-escalation technique training could involve refining of: a. Verbal communication techniques; b. Use of body language; c. Prevention and recognition strategies (risk assessment tools); d. Staff attitudes, knowledge and skills; e. Setting of limits for patients to follow; f. Environmental controls (such as minimising light, noise, conversations and so on) used for the management of aggression - or any combination of these.
Outcomes	Primarily routinely-recorded binary outcomes. 1. Clinically important changes in global state (short-term outcomes) 2. Aggression 2.1 Improved to an important extent 2.2 Deterioration: incidence of violence to self or others (harm) 2.3 Changes in aggression as recorded by any other outcomes 2.4 Recurrence of aggression 3. Adverse effects 3.1 Physical adverse effects 3.2 Death, suicide or natural causes 3.3 Psychological adverse effects 4. Service outcomes 4.1 Time in hospital

Table 2. Outline design for a randomised trial of de-escalation technique *(Continued)*

	5. Acceptability
	5.1 To staff
	5.2 To patients
	6. Cost
Notes	* We are unclear of power calculations at this point. It is likely that the sample of people will have to total at least 300 to gain sufficient power to find clear outcomes that are likely to effect clinical practice, but this figure would have to be modified depending on a well-researched (not imputed) ICC.

APPENDICES

Appendix 1. Previous searches

1.1 Search in 2009, 2012 and 2014

1.1.1 Electronic searches

1.1.1.1 Cochrane Schizophrenia Group's Study-Based Register of Trials

We searched this register (June 16, 2009; March 22, 2012; July 25, 2012; May 13, 2014) using the following search strategy:

[(*aggress* or *agitat* or *violen*) and (*de-escalat* or *deescalat* or *de-stimulat* or *destimulat* or *de-fus* or *defus* or *one-to-one* or *one to one* or *diffuse* or *calming* or *non aversive* or *non-aversive* or *non confrontat* or *non-confrontat* or *psycho social* or *psycho-social* or *verbal* or *non verbal* or *non-verbal* or *talk* (*talk* and *down*) *nurses role*) in title abstract and index terms of REFERENCE]

This register is compiled by systematic searches of major databases, handsearches and conference proceedings (see [Group's Module](#)).

1.1.2 Searching other resources

1.1.2.1 Reference searching

We inspected the references of all identified studies for further relevant studies.

1.1.2.2 Personal contact

We contacted the first author of each included study for information regarding unpublished trials.

WHAT'S NEW

Date	Event	Description
10 April 2017	Amended	Review author, Harish Rao, affiliation updated. Reference LYPFT 2013 updated. Text in Authors' conclusions amended.

CONTRIBUTIONS OF AUTHORS

HR and MJ devised the protocol for the study.

HR and WY reviewed the abstracts of the studies obtained from the search.

MJ reviewed the abstracts of a random sample of the search studies.

MD, SY, WS and HR completed the first draft of this review manuscript.

MD and SZ revised the review manuscript.

De-escalation techniques for psychosis-induced aggression or agitation (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

XM and JX reviewed and final proofed the manuscript.

DECLARATIONS OF INTEREST

All review authors have no known conflicts of interest.

Review authors JX and SZ work for Systematic Review Solutions which is an independent health care research company.

SOURCES OF SUPPORT

Internal sources

- Leeds PFT, UK.

External sources

- Inner Mongolia Medical University, Inner Mongolia, China.

One million projects of Science and Technology. Project code: YKD2013KJBW006

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We have amended the objective of the review and description of participants to reflect our title more accurately, that is, to investigate effects of de-escalation techniques in the management of aggression due to psychosis. We have stated the age of participants more clearly.

We have also updated [Types of interventions](#) to clarify the description of de-escalation techniques.

For [Types of outcome measures](#), we added adverse events as a primary outcome and an outcome of interest for the 'Summary of findings' table.

A new team of authors joined the original review authors of the protocol and helped to complete the review.

INDEX TERMS

Medical Subject Headings (MeSH)

*Aggression; Behavior Control; Crisis Intervention [methods]; Psychomotor Agitation [*prevention & control]; Psychotic Disorders [*psychology]

MeSH check words

Humans